21,000 Shares in Harrow, Inc. (NASDAQ:HROW) Acquired by Hussman Strategic Advisors Inc.

Hussman Strategic Advisors Inc. bought a new stake in Harrow, Inc. (NASDAQ:HROW - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 21,000 shares of the company's stock, valued at approximately $559,000. Hussman Strategic Advisors Inc. owned about 0.06% of Harrow at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in HROW. GF Fund Management CO. LTD. purchased a new position in Harrow in the fourth quarter valued at approximately $25,000. Tower Research Capital LLC TRC lifted its holdings in Harrow by 769.5% in the fourth quarter. Tower Research Capital LLC TRC now owns 1,652 shares of the company's stock valued at $55,000 after acquiring an additional 1,462 shares during the period. Aquatic Capital Management LLC purchased a new stake in shares of Harrow in the 4th quarter worth about $78,000. GAMMA Investing LLC boosted its position in shares of Harrow by 2,401.2% in the 1st quarter. GAMMA Investing LLC now owns 6,278 shares of the company's stock worth $1,670,000 after buying an additional 6,027 shares in the last quarter. Finally, Federated Hermes Inc. acquired a new position in Harrow in the 4th quarter valued at about $214,000. Institutional investors and hedge funds own 72.76% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on HROW shares. Cantor Fitzgerald started coverage on Harrow in a research report on Friday, July 11th. They issued an "overweight" rating and a $76.00 target price on the stock. B. Riley lowered their price objective on Harrow from $69.00 to $65.00 and set a "buy" rating for the company in a research note on Tuesday, April 1st. William Blair assumed coverage on Harrow in a research note on Tuesday, June 10th. They set an "outperform" rating for the company. HC Wainwright upped their price objective on Harrow from $57.00 to $60.00 and gave the stock a "buy" rating in a research note on Monday, May 12th. Finally, BTIG Research began coverage on Harrow in a research note on Thursday, June 12th. They set a "buy" rating and a $62.00 price objective for the company. Seven analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $63.83.

Harrow Trading Down 0.7%

Shares of NASDAQ HROW traded down $0.25 during midday trading on Friday, hitting $35.89. The stock had a trading volume of 482,017 shares, compared to its average volume of 500,904. The company's 50-day simple moving average is $30.13 and its 200 day simple moving average is $28.84. The firm has a market cap of $1.32 billion, a P/E ratio of -64.09 and a beta of 0.41. Harrow, Inc. has a fifty-two week low of $20.85 and a fifty-two week high of $59.23. The company has a debt-to-equity ratio of 2.01, a current ratio of 0.91 and a quick ratio of 0.85.

Harrow (NASDAQ:HROW - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.38) EPS for the quarter, missing the consensus estimate of $0.02 by ($0.40). Harrow had a negative net margin of 10.19% and a negative return on equity of 25.01%. The firm had revenue of $47.83 million during the quarter, compared to analyst estimates of $57.00 million. Research analysts anticipate that Harrow, Inc. will post -0.53 EPS for the current year.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.